Standard BioTools Inc. Files 8-K on Financials
Ticker: LAB · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1162194
| Field | Detail |
|---|---|
| Company | Standard Biotools Inc. (LAB) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, company-update
Related Tickers: LAB
TL;DR
Standard BioTools (LAB) filed an 8-K on Aug 11, 2025, covering financials and operations.
AI Summary
Standard BioTools Inc. filed an 8-K on August 11, 2025, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure and financial statements and exhibits. The company was formerly known as Fluidigm Corp until November 13, 2001.
Why It Matters
This 8-K filing provides investors with crucial updates on Standard BioTools Inc.'s financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial and operational information, not indicating any immediate or significant new risks.
Key Players & Entities
- STANDARD BIOTOOLS INC. (company) — Registrant
- August 11, 2025 (date) — Date of Report
- FLUIDIGM CORP (company) — Former Company Name
- November 13, 2001 (date) — Date of Name Change
- 2 TOWER PLACE , SUITE 2000 (address) — Principal Executive Offices
- South San Francisco , California 94080 (address) — Principal Executive Offices
- 650 ) 266-6000 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Standard BioTools Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as provide Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed as of August 11, 2025.
What was Standard BioTools Inc. formerly known as?
Standard BioTools Inc. was formerly known as FLUIDIGM CORP.
On what date did the company change its name from Fluidigm Corp?
The date of the name change was November 13, 2001.
Where are Standard BioTools Inc.'s principal executive offices located?
The principal executive offices are located at 2 Tower Place, Suite 2000, South San Francisco, California 94080.
Filing Stats: 602 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-11 17:00:32
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob
Filing Documents
- lab-20250811.htm (8-K) — 54KB
- lab-ex99_1.htm (EX-99.1) — 1656KB
- img96762296_0.jpg (GRAPHIC) — 147KB
- 0000950170-25-106636.txt ( ) — 2112KB
- lab-20250811.xsd (EX-101.SCH) — 51KB
- lab-20250811_htm.xml (XML) — 5KB
02 - Results of Operations and Financial Condition
Item 2.02 - Results of Operations and Financial Condition On August 11, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading "Full Year 2025 Revenue Outlook" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. The information set forth under the heading "Full Year 2025 Revenue Outlook" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Standard BioTools Inc., dated August 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 11, 2025 STANDARD BIOTOOLS INC. By: /s/ Alex Kim Name: Alex Kim Title: Chief Financial Officer (Principal Financial and Accounting Officer)